Healthcare Private Equity Returns Trailed Broader Market
Recent vintage healthcare private equity funds have lagged behind the performance of broader asset classes.
Updated on Oct. 5, 2026 in Healthcare
Live Poll
Do you trust that larger, consolidated investment funds provide better returns than specialized, boutique firms?
Healthcare private equity funds launched between 2021 and 2023 posted a 10.2% pooled internal rate of return, falling short of the 12% average recorded by all private equity funds in that period. This marks a notable shift from the 2012-2014 period when healthcare specialist funds significantly outperformed the wider market.
Why it matters
The performance decline is largely attributed to high entry valuations during the 2021 market peak combined with increased competition as generalist firms expanded into healthcare. The influx of capital and crowded deal flow have effectively compressed the historical performance advantage previously seen in the sector.
Healthcare private equity funds raised $16.2 billion in H1 2026, capturing 6.1% of total private equity capital. The sector is on track for a 50% decline in total fund count throughout 2026 compared to 2025.
The players
Blackstone
Blackstone is a major global alternative asset manager that operates extensive private equity and life sciences investment platforms.
Patient Square Capital
Patient Square Capital is a healthcare-dedicated investment firm that manages large-scale capital specifically for health sector assets.
The details
Capital is increasingly concentrating in fewer, larger funds that employ thematic investment strategies, such as the $6.3 billion life sciences fund closed by Blackstone in March and the $4.4 billion fund closed by Patient Square Capital in May. Only 11 healthcare-focused private equity funds successfully closed in the first half of 2026 as generalist firms continue to intensify competition for assets.
Timeline
2012-2014 was a period when healthcare private equity outperformed the broader market.
2021-2023 funds are currently trailing broader market returns.
March 2026 saw Blackstone close a $6.3 billion life sciences fund.
May 2026 marked the closure of a $4.4 billion fund by Patient Square Capital.
H1 2026 recorded 11 total healthcare private equity fund closures.
Market Landscape
This performance trend reflects a broader shift toward consolidation where capital is increasingly locked into large, thematic funds rather than smaller specialist vehicles. As generalist firms crowd the space, specialized healthcare funds are struggling to maintain the premium returns that once defined the niche.
For institutional investors and limited partners, this trend suggests a potential need to reassess allocations toward healthcare-specific vehicles following the valuation pressures of recent years. Consumers may see fewer independent healthcare providers as capital consolidates into larger, thematic portfolios managed by massive asset firms.
The takeaway
The era of easy outperformance for healthcare-focused private equity funds appears to be moderating as entry valuations and market competition increase. Investors should remain cautious of the long-term cycle performance for funds raised during the 2021 market peak.
Further reading
For more on industry trends, visit the Healthcare section.
Source note: This article includes information reported by Pitchbook.
Live Poll
Do you trust that larger, consolidated investment funds provide better returns than specialized, boutique firms?
